Muriel Liberto, PhD

Mintz

+ Follow Contact

Latest Posts › Product of Nature Doctrine

Share:

With its Vanda Pharma and Berkheimer Memos, USPTO Provides Increased Clarity and Predictability in the Patent Eligibility...

In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed. Cir. 2018), we have had more good news for the patent eligibility of claims...more

7/23/2018 / Intellectual Property Protection , Mayo v. Prometheus , Patent-Eligible Subject Matter , Patents , Personalized Medicine , Pharmaceutical Patents , Product of Nature Doctrine , USPTO

With its Vanda Pharma and Berkheimer memos, USPTO provides increased clarity around personalized medicine patent eligibility

In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed. Cir. 2018) the US Patent and Trademark Office (USPTO) has issued two memos...more

6/25/2018 / Evidence , Intellectual Property Protection , Patent Examinations , Patent-Eligible Subject Matter , Patents , Personalized Medicine , Pharmaceutical Patents , Product of Nature Doctrine , USPTO

Personalized Medicine Gets a Boost from Federal Circuit’s Vanda Pharma Decision

The Federal Circuit provided a welcome boost for stakeholders in the field of personalized medicine with its recent decision in Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. (2016-2702, 2016-2708 April 13, 2018). Vanda...more

4/23/2018 / Intellectual Property Protection , Mayo v. Prometheus , Patent-Eligible Subject Matter , Patents , Personalized Medicine , Pharmaceutical Patents , Product of Nature Doctrine

3 Results

View per page

Page: of 1